PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15019051

Immunoaffinity solid-phase extraction for pharmaceutical and biomedical trace-analysis-coupling with HPLC and CE-perspectives.

N Delaunay-Bertoncini·M-C Hennion
View original source ↗Export metadata ↓

Abstract

Immunoaffinity solid-phase extraction (SPE) technique is based upon a molecular recognition mechanism. The high affinity and the high selectivity of the antigen-antibody interactions allow the specific extraction and the concentration of the analytes of interest in one step. In pharmaceutical and biological fields, where most often matrices are complex and analytes at trace-levels, this approach constitutes a unique tool for fast and solvent-free sample preparation. This review presents a general description of this extraction technique and gives numerous examples of its applications in pharmaceutical and biomedical fields. It emphasizes the on-line coupling with chromatographic and electrophoretic separation techniques and introduces new developments. The future directions, especially with regards to the current development of analytical microsystems, are discussed.

Explore related subjects

AntibodiesChromatography, AffinityChromatography, High Pressure LiquidElectrophoresis, CapillaryForecastingFranceImmunoassayMolecular WeightPharmaceutical PreparationsTrace ElementsJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

N Delaunay-Bertoncini, M-C Hennion. 2004-03-01. Immunoaffinity solid-phase extraction for pharmaceutical and biomedical trace-analysis-coupling with HPLC and CE-perspectives.. https://doi.org/10.1016/s0731-7085(03)00559-4

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2021

ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.

In glioblastoma (GBM), the most frequent and lethal brain tumor, therapies suppressing recurrently altered signaling pathways failed to extend survival. However, in patient subsets, specific genetic lesions can confer sensitivity to targeted agents. By exploiting an integrated model based on patient-derived stem-like cells, faithfully recapitulating the original GBMs in vitro and in vivo, here, we identify a human GBM subset (∼9% of all GBMs) characterized by ERBB3 overexpression and nuclear accumulation. ERBB3 overexpression is driven by inheritable promoter methylation or post-transcriptional silencing of the oncosuppressor miR-205 and sustains the malignant phenotype. Overexpressed ERBB3 behaves as a specific signaling platform for fibroblast growth factor receptor (FGFR), driving PI3K/AKT/mTOR pathway hyperactivation, and overall metabolic upregulation. As a result, ERBB3 inhibition by specific antibodies is lethal for GBM stem-like cells and xenotransplants. These findings highlight a subset of patients eligible for ERBB3-targeted therapy.

Antibodies↗
PubMed2006

A simple and reliable method for the detection of sialylation in complex/hybrid-type carbohydrate chains of glycoproteins by mixed lectins.

A practical and convenient method for discriminating between the presence and the absence of sialic acid in carbohydrate chains of glycoproteins was devised using paramagnetic beads and two lectins, Sambucus sieboldiana lectin (SSA) and Ricinus communis agglutinin (RCA120). The glycoproteins of transferrin or thyroglobulin were firstly captured to paramagnetic beads that were previously coated with corresponding antibody, and then the lectins of RCA120-biotin and SSA-FITC were bound to the glycoproteins on the paramagnetic beads. Finally, the fluorescence intensity of the beads was measured to determine the ratios of lectins RCA120-biotin/Cy5-streptavidin to SSA-FITC. The mixed lectins method showed bigger difference of the ratios between the presence and the absence of sialic acid, indicating higher discrimination efficiency than the ordinary non-mixed lectins method. Furthermore, statistical analysis by two-side t-test indicated that the mixed lectins method was more highly reliable than the ordinary non-mixed lectins method in discriminating between the presence and the absence of sialic acid. The reaction with the two lectins can be performed in a single tube and readily automated taking advantage of the use of paramagnetic beads.

Antibodies↗
PubMed2006

Novel probes for protein chip applications.

Protein microarrays (protein chips), due to their high throughput, have great potential to reduce the cycle time of drug discovery and to improve the efficiency of medical diagnostics. A great deal of effort has been made to facilitate the development of protein chips, such as the antibody microarrays. High-throughput fabrication of purified high-affinity probes is now one of the bottlenecks for protein microarrays. We discuss here three novel strategies to fabricate probes, namely, single chain antibodies displayed by phage, protein-oligonucleotide conjugates, and aptamers, which are promising in the protein chip technology.

Antibodies↗